Subcutaneous Epcoritamab in Combination with Rituximab plus Lenalidomide (R2) for First-Line Treatment of Follicular Lymphoma: Initial Results from Phase 1/2 Trial

被引：11

作者：

Falchi, Lorenzo ^{[1
]}

Leslie, Lori A. ^{[2
]}

Belada, David ^{[3
]}

Kopeckova, Katerina ^{[4
]}

Offner, Fritz ^{[5
]}

Brody, Joshua ^{[6
]}

Canales, Miguel ^{[7
]}

Martin Garcia-Sancho, Alejandro ^{[8
]}

Nijland, Marcel ^{[9
,10
]}

Andersson, P-O ^{[11
]}

Awan, Farrukh T. ^{[12
]}

Christensen, Jacob Haaber ^{[13
]}

Drott, Kristina ^{[14
]}

Hellstrom, Mats ^{[15
]}

Lewerin, Catharina ^{[16
]}

Narkhede, Mayur ^{[17
]}

Snauwaert, Sylvia ^{[18
]}

Wahlin, Bjorn E. ^{[19
]}

Rana, Ali ^{[20
]}

Abbas, Aqeel ^{[20
]}

Wang, Liwei ^{[20
]}

Minh Dinh ^{[21
]}

Vermaat, Joost S. P. ^{[22
]}

Abrisqueta, Pau ^{[23
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, Lymphoma Serv, New York, NY USA

[2] Hackensack Univ, Med Ctr, Hackensack, NJ USA

[3] Charles Univ Prague, Hosp & Fac Med, Dept Internal Med Hematol 4, Hradec Kralove, Czech Republic

[4] Fak Nemocnice Motole, Prague, Czech Republic

[5] Univ Ziekenhuis Gent, Ghent, Belgium

[6] Icahn Sch Med Mt Sinai, New York, NY USA

[7] Hosp Univ La Paz, Madrid, Spain

[8] Hosp Univ Salamanca, Salamanca, Spain

[9] Univ Med Ctr Groningen, Dept Hematol, Groningen, Netherlands

[10] Univ Groningen, Groningen, Netherlands

[11] Sodra Alvsborgs Sjukhus, Boras, Sweden

[12] Univ Texas Southwestern Med Ctr, Dallas, TX USA

[13] Odense Univ Hosp, Odense, Denmark

[14] Skane Univ Hosp, Lund, Sweden

[15] Uppsala Univ Hosp, Uppsala, Sweden

[16] Sahlgrens Univ Hosp, Gothenburg, Sweden

[17] UAB, ONeal Comprehens Canc Ctr, Birmingham, AL USA

[18] AZ Sint Jan Brugge, Dept Hematol, Brugge, Belgium

[19] Karolinska Inst, Stockholm, Sweden

[20] Genmab, Princeton, NJ USA

[21] AbbVie Inc, N Chicago, IL USA

[22] Leiden Univ, Med Ctr, Dept Hematol, Leiden, Netherlands

[23] Hosp Univ Vall dHebron, Barcelona, Spain

来源：

BLOOD | 2022年 / 140卷

关键词：

D O I：

10.1182/blood-2022-158232

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1471 / 1473

页数：3

共 50 条

[41] Epcoritamab SC With Rituximab plus Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma, Including Patients With POD24: Updated Results From EPCORE NHL-2 [J].

Merryman, Reid W. ;

Belada, David ;

Sureda, Anna ;

Leppa, Sirpa ;

Vermaat, Joost S. P. ;

Holte, Harald ;

Hutchings, Martin ;

Lugtenburg, Pieternella ;

de Vos, Sven ;

Abrisqueta, Pau ;

Nijland, Marcel ;

Christensen, Jacob Haaber ;

Wahlin, Bjorn E. ;

Linton, Kim M. ;

Wang Liwei ;

Abbas, Aqeel ;

Rana, Ali ;

Quadri, Syed ;

Falchi, Lorenzo .

AMERICAN JOURNAL OF HEMATOLOGY, 2023, 98 :S37-S38

[42] Lenalidomide in combination with R-CHOP (R2-CHOP) as first-line treatment of patients with high tumour burden follicular lymphoma: a single-arm, open-label, phase 2 study [J].

Tilly, Herve ;

Morschhauser, Franck ;

Casasnovas, Olivier ;

Molina, Thierry Jo ;

Feugier, Pierre ;

Le Gouill, Steven ;

Haioun, Corinne ;

Tournilhac, Olivier ;

Bouabdallah, Reda ;

Gabarre, Jean ;

Lamy, Thierry ;

Cabecadas, Jose ;

Becker, Stephanie ;

Jardin, Fabrice ;

Mounier, Nicolas ;

Salles, Gilles .

LANCET HAEMATOLOGY, 2018, 5 (09) :E403-E410

[43] Ten Year Follow up of the MD Anderson Cancer Center Phase 2 Study of Rituximab in Combination with Lenalidomide (R2) for Patients with Low Tumor Burden Follicular Lymphoma [J].

Chihara, Dai ;

Nastoupil, Loretta ;

Strati, Paolo ;

Samaniego, Felipe ;

Feng, Lei ;

Rodriguez, Maria Alma ;

Fayad, Luis ;

Westin, Jason R. ;

Hagemeister, Fredrick B. ;

Wang, Michael ;

Neelapu, Sattva S. ;

Fowler, Nathan H. .

BLOOD, 2021, 138

[44] SUBCUTANEOUS RITUXIMAB AND CHEMOTHERAPY ACHIEVES SIMILAR TROUGH LEVELS, SAFETY, AND RESPONSE AS INTRAVENOUS RITUXIMAB IN FIRST-LINE FOLLICULAR LYMPHOMA: STAGE 1 RESULTS OF THE PHASE 3 SABRINA STUDY [J].

Davies, A. ;

Merli, F. ;

Mihaljevic, B. ;

Siritanaratkul, N. ;

Solal-Celigny, P. ;

Boehnke, A. ;

Berge, C. ;

McIntyre, C. ;

Barrett, M. ;

MacDonald, D. .

HAEMATOLOGICA, 2013, 98 :131-132

[45] Phase 3 trial of odronextamab plus lenalidomide versus rituximab plus lenalidomide in relapsed/refractory (R/R) follicular lymphoma (FL) and marginal zone lymphoma (MZL; OLYMPIA-5). [J].

Vitolo, Umberto ;

Merli, Michele ;

Norasetthada, Lalita ;

Wassenaar, Timothy Robert ;

Martin, Eva Maria Donato ;

Bobillo, Sabela ;

Shen, Biyi ;

Flink, Dina M. ;

Zhu, Min ;

Chandrasekharan, Soujanya ;

Brouwer-Visser, Jurriaan ;

Chaudhry, Aafia ;

Mohamed, Hesham ;

Ambati, Srikanth R. ;

Cordoba, Raul .

JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)

[46] Tafasitamab Plus Lenalidomide and Rituximab for Relapsed or Refractory Follicular Lymphoma: Results from a Phase 3 Study (inMIND) [J].

Sehn, Laurie H. ;

Luminari, Stefano ;

Scholz, Christian W. ;

Huebel, Kai ;

Salar, Antonio ;

Paneesha, Shankara ;

Wahlin, Bjorn E. ;

Panayiotidis, Panayiotis ;

Lee, Hui-Peng ;

Ubieto, Ana Jimenez ;

Sancho, Juan-Manuel ;

Kim, Tae Min ;

Domenech, Eva Domingo ;

Kumode, Takahiro ;

Poh, Christina ;

Thieblemont, Catherine ;

Deeren, Dries ;

de Wit, Edwin ;

Arbushites, Michael ;

Casadebaig, Marie-Laure ;

Trneny, Marek .

BLOOD, 2024, 144 :LBA1-LBA4

[47] Ibrutinib Plus Rituximab in Treatment-Naive Patients with Follicular Lymphoma: Results from a Multicenter, Phase 2 Study [J].

Fowler, Nathan ;

Nastoupil, Loretta ;

de Vos, Sven ;

Knapp, Mark ;

Flinn, Ian W. ;

Chen, Robert ;

Advani, Ranjana H. ;

Bhatia, Sumeet ;

Martin, Peter ;

Mena, Raul ;

Suzuki, Samuel ;

Beaupre, Darrin M. ;

Neuenburg, Jutta K. ;

Palomba, M. Lia .

BLOOD, 2015, 126 (23)

[48] Cost-Effectiveness Analysis of Bendamustine Plus Rituximab as a First-Line Treatment for Patients with Follicular Lymphoma in Spain [J].

Eliazar Sabater ;

Armando López-Guillermo ;

Antonio Rueda ;

Antonio Salar ;

Itziar Oyagüez ;

Juan Manuel Collar .

Applied Health Economics and Health Policy, 2016, 14 :465-477

[49] Cost-Effectiveness Analysis of Bendamustine Plus Rituximab as a First-Line Treatment for Patients with Follicular Lymphoma in Spain [J].

Sabater, Eliazar ;

Lopez-Guillermo, Armando ;

Rueda, Antonio ;

Salar, Antonio ;

Oyaguez, Itziar ;

Manuel Collar, Juan .

APPLIED HEALTH ECONOMICS AND HEALTH POLICY, 2016, 14 (04) :465-477

[50] PERSPECTIVE: A Randomized, Phase 3 Study of Ibrutinib-Rituximab Versus Placebo-Rituximab Combination Therapy for First-Line Treatment of Follicular Lymphoma [J].

Flinn, Ian ;

Gordon, Leo ;

Rule, Simon ;

Chen, Robert ;

Kwei, Long ;

Chu, Alvina ;

Fowler, Nathan .

AMERICAN JOURNAL OF HEMATOLOGY, 2020, 95 :S12-S13

← 1 2 3 4 5 →